Phytotherapy of benign prostatic hyperplasia. A minireview

Phytotherapy Research

Volumn 28, Issue 7, 2014, Pages 949-955

  Pagano, Ester ^a   Laudato, Massimiliano ^a,b   Griffo, Michele ^a,b   Capasso, Raffaele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Farmacia S Anna   (Italy)

Author keywords

benign prostatic hyperplasia; isoflavones; lycopene; nettle; nutraceuticals; pygeum; saw palmetto; soy isoflavones

Indexed keywords

CERNITIN; CURCUMIN; DUTASTERIDE; FINASTERIDE; HERBACEOUS AGENT; ISOFLAVONE DERIVATIVE; LYCOPENE; NUTRACEUTICAL; PLACEBO; QUERCETIN; SABAL EXTRACT; SELENIUM; SITOSTEROL;

BIOCHEMICAL COMPOSITION; CLINICAL EFFECTIVENESS; CUCURBITA PEPO; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HERBAL MEDICINE; HUMAN; IMPOTENCE; LIBIDO DISORDER; NONHUMAN; PATIENT SAFETY; PHYTOCHEMISTRY; PHYTOTHERAPY; PROSTATE HYPERTROPHY; PYGEUM; REVIEW; SABAL; SQUASH; URINARY TRACT DISEASE; URTICA DIOICA;

CUCURBITA PEPO; PRUNUS AFRICANA; PYGEUM; SERENOA REPENS; URTICA; URTICA DIOICA;

DIETARY SUPPLEMENTS; HUMANS; MALE; PHYTOTHERAPY; PROSTATIC HYPERPLASIA;

EID: 84904260409     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5084     Document Type: Review

References (52)

1. Abrams P, Chapple c C, Khoury S, Roehrborn C, de la Rosette J,. 2013. International Consultation on New Developments in Prostate Cancer and Prostate Diseases: evaluation and treatment of lower urinary tract symptoms in older men. J Urol 189: S93-S101.
2. Agbabiaka TB, Pittler MH, Wider B, Ernst E,. 2009. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf 32: 637-647.
3. Altavilla D, Bitto A, Polito F, et al,. 2011. The combination of Serenoa repens, selenium and lycopene is more effective than Serenoa repens alone to prevent hormone dependent prostatic growth. J Urol 186: 1524-1529.
4. Azimi H, Khakshur AA, Aghdasi I, Fallah-Tafti M, Abdollahi M,. 2012. A review of animal and human studies for management of benign prostatic hyperplasia with natural products: perspective of new pharmacological agents. Inflamm Allergy Drug Targets 11: 207-221.
5. Barrera LN, Cassidy A, Johnson IT, Bao Y, Belshaw NJ,. 2012. Epigenetic and antioxidant effects of dietary isothiocyanates and selenium: potential implications for cancer chemoprevention. Proc Nutr Soc 71: 237-245.
6. Bent S, Kane C, Shinohara K, et al,. 2006. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 354: 557-566. (Pubitemid 43209103)
7. Bertaccini A, Giampaoli M, Cividini R, et al,. 2012. Observational database Serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project. Arch Ital Urol Androl 84: 117-122.
8. Blumenthal M,. 1998. The Complete German Commission E Monographs. American Botanical Council: Austin USA.
9. Bonvissuto G, Minutoli L, Morgia G, et al,. 2011. Effect of Serenoa repens, lycopene, and selenium on proinflammatory phenotype activation: an in vitro and in vivo comparison study. Urology 77: 248.e9-16.
10. Bowen P, Chen L, Stacewicz-Sapuntzakis M, et al,. 2002. Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis. Exp Biol Med 227: 886-893. (Pubitemid 35340343)
11. Boyle P, Robertson C, Lowe F, Roehrborn C,. 2004. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 93: 751-756. (Pubitemid 38497023)
12. Cai T, Mazzoli S, Bechi A, et al,. 2009. Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. Int J Antimicrob Agents 33: 549-353.
13. Capasso F, Gaginella TS, Grandolini G, Izzo AA,. 2003. Phytotherapy. A Quick Reference to Herbal Medicine. Springer-Verlag: Berlin.
14. Clark LC, Combs GF Jr, Turnbull BW, et al,. 1996. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276: 1957-1963. (Pubitemid 26427723)
15. Clinton SK, Emenhiser C, Schwartz SJ, et al,. 1996. Cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev 5: 823-833. (Pubitemid 26346282)
16. Dedhia RC, McVary KT,. 2008. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 179: 2119-2125.
17. Edwards JL,. 2008. Diagnosis and management of benign prostatic hyperplasia. Am Fam Physician 77: 1403-1410.
18. Edwards JE, Moore RA,. 2002. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol 2: 14.
19. El-Bayoumy K, Upadhyaya P, Date V, Sohn OS, Fiala ES, Reddy B,. 1991. Metabolism of [14C]benzyl selenocyanate in the F344 rat. Chem Res Toxicol 4: 560-565.
20. El-Bayoumy K, Das A, Narayanan B, et al,. 2006. Molecular targets of the chemopreventive agent 1,4-phenylenebis (methylene)-selenocyanate in human non-small cell lung cancer. Carcinogenesis 27: 1369-1376. (Pubitemid 43985412)
21. Ford NA, Erdman JW Jr., 2012. Are lycopene metabolites metabolically active? Acta Biochim Pol 59: 1-4.
22. Ghorbanibirgani A, Khalili A, Zamani L,. 2013. The efficacy of stinging nettle (Urtica dioica) in patients with benign prostatic hyperplasia: a randomized double-blind study in 100 patients. Iran Red Crescent Med J 15: 9-10.
23. Gorski JC, Huang SM, Pinto A, et al,. 2004. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 75: 89-100. (Pubitemid 38130121)
24. Goyal A, Delves GH, Chopra M, Lwaleed BA, Cooper AJ,. 2006. Prostate cells exposed to lycopene in vitro liberate lycopene-enriched exosomes. BJU Int 98: 907-911. (Pubitemid 44368048)
25. Herzog A, Siler U, Spitzer V, et al,. 2005. Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J 19: 272-274. (Pubitemid 40189279)
26. Izzo AA,. 2012. Interactions between herbs and conventional drugs: overview of the clinical data. Med Princ Pract 21: 404-428.
27. Jacobsen BK, Knutsen SF, Fraser GE,. 1998. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 9: 553-557. (Pubitemid 29046127)
28. Kim TH, Lim HJ, Kim MS, Lee MS,. 2012. Dietary supplements for benign prostatic hyperplasia: an overview of systematic reviews. Maturitas 73: 180-185.
29. Laudato M, Pescitelli L, Capasso R,. 2013. Natural products of mineral origin. Nat Prod Commun 8: 419-423.
30. MacDonald R, Ishani A, Rutks I, Wilt TJ,. 2000. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int 85: 836-841. (Pubitemid 30242787)
31. MacDonald R, Tacklind JW, Rutks I, Wilt TJ,. 2012. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int 109: 1756-1761.
32. Magri V, Trinchieri A, Pozzi G, et al,. 2007. Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis. Int J Antimicrob Agents 29: 549-556. (Pubitemid 46578189)
33. Mantovani F,. 2010. Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. Minerva Urol Nefrol 62: 335-340.
34. Markowitz JS, Donovan JL, Devane CL, et al,. 2003. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 74: 536-542. (Pubitemid 37521997)
35. Melo EA, Bertero EB, Rios LA, Mattos D Jr., 2002. Evaluating the efficiency of a combination of Pygeum africanum and stinging nettle (Urtica dioica) extracts in treating benign prostatic hyperplasia (BPH): double-blind, randomized, placebo controlled trial. Int Braz J Urol 28: 418-425. (Pubitemid 36322450)
36. Minutoli L, Bitto A, Squadrito F, et al,. 2013. Serenoa repens, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasia. Curr Med Chem 20: 1306-1312.
37. Morán E, Budía A, Broseta E, Boronat F,. 2013. Phytotherapy in urology. Current scientific evidence of its application in benign prostatic hyperplasia and prostate adenocarcinoma. Actas Urol Esp 37: 114-119.
38. Morgia G, Mucciardi G, Galì A, et al,. 2010. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. Urol Int 84: 400-406.
39. Morton MS, Chan PS, Cheng C, et al,. 1997. Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong, and the United Kingdom. Prostate 32: 122-128. (Pubitemid 27280356)
40. Nickel JC, Sander S, Moon TD,. 2008. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 62: 1547-1559.
41. Obermüller-Jevic UC, Olano-Martin E, Corbacho AM, et al,. 2003. Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. J Nutr 133: 3356-3360. (Pubitemid 37409459)
42. Rayman MP,. 2005. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 64: 527-542. (Pubitemid 41705454)
43. Safarinejad MR,. 2005. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother 5: 1-11.
44. ®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma. J Inflamm 10: 11.
45. Tacklind J, MacDonald R, Rutks I, Wilt TJ,. 2009. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 15: CD001423.
46. Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ,. 2012. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 12: CD001423.
47. Wein A, Novick A, Partin A, Peters C,. 2011. Campbell-Walsh Urology. Saunders: Philadelphia USA.
48. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C,. 1998. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 280: 1604-1609. (Pubitemid 28520650)
49. Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J,. 2000. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev 2: CD001043.
50. Wilt T, Ishani A, MacDonald R,. 2002. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 3: CD001423.
51. Wong SY, Lau WW, Leung PC, Leung JC, Woo J,. 2007. The association between isoflavone and lower urinary tract symptoms in elderly men. Br J Nutr 98: 1237-1242. (Pubitemid 350193791)
52. Wong WC, Wong EL, Li H, et al,. 2012. Isoflavones in treating watchful waiting benign prostate hyperplasia: a double-blinded, randomized controlled trial. J Altern Complement Med 18: 54-60.